Brivaracetam

Brivaracetam Process Related & Degradation Impurities / Brivaracetam Related Compounds / Reference Standards

Explore a comprehensive range of Brivaracetam impurities and reference standards essential for pharmaceutical research.

Brivaracetam is a selective synaptic vesicle protein 2A (SV2A) ligand used as an adjunctive therapy for partial-onset seizures in patients with epilepsy. It offers rapid brain penetration and consistent seizure control with minimal drug interactions, making it suitable for long-term management.

These compounds support various stages of drug development. This includes product formulation, Abbreviated New Drug Application (ANDA), Drug Master Files (DMFs) submissions, and manufacturing. They are critical for conducting quality assessments, stability studies, and genotoxicity evaluations of Brivaracetam and its related products.

SynThink is a trusted provider of high-quality Brivaracetam impurities, including: Degradation impurities; Genotoxic impurities; Process-related impurities; EP / USP-compliant reference standards and Nitrosamine impurities.

We rigorously characterize and re-test the compounds at regular intervals to ensure consistency and compliance. We supply each product with a detailed Certificate of Analysis (CoA) and comprehensive analytical data, meeting global regulatory standards.